Search En menu en ClientConnect
Search
Results
Top 5 search results See all results Advanced search
Top searches
Most visited pages
Reference: 20190824
Release date: 9 February 2023

Promoter – Financial Intermediary

DEEPULL DIAGNOSTICS SL

Location

Description

The loan will enable the promoter to increase its research, development and innovation (RDI) activities for its highly innovative easy-to-use diagnostics platform to accelerate and improve accuracy in acute infections and sepsis diagnosis. The project is financed under the Infectious Diseases Finance Facility (IDFF) set up as part of Horizon 2020, the European Union's research and innovation programme for 2014-2020.

Additionality and Impact

The project addresses the failure in financial markets for small innovative and high-growth companies arising from the limited access and/or prohibitive cost of financing charged by creditors/investors as a result from information asymmetries, higher uncertainty, lack of collateral and imperfect screening and monitoring. The project is in line with the objectives of Horizon Europe program. The project will deliver a testing platform for sepsis based on PCR which has a broad application in diagnostic of sepsis and antimicrobial resistance (AMR). EIB's financing would be complementary to European VC investors and would provide a signalling effect to crowd-in other capital providers, which are necessary for the completion of the product development stage and commencing commercial operations.  EIB provides long term Venture Debt financing, with longer availability and maturity than the Company would otherwise be able to raise from the markets.

Objectives

The related RDI activities aim to fight sepsis and antimicrobial resistance, through a faster and automated diagnostics system, based on a culture-free/label-free comprehensive microbial identification. In detail, a faster pathogen identification and antimicrobial susceptibility testing (AST), combined with an early warning classifier system, will allow making diagnosis faster and more accurate, thus helping to reduce mortality and morbidity related to sepsis and antimicrobial resistance.

Sector(s)

Proposed EIB finance (Approximate amount)

EUR 20 million

Total cost (Approximate amount)

EUR 55 million

Environmental aspects

The RDI activities are expected to be carried out in existing facilities that are already used for the same purposes and that are not expected to change their scope due to the project. An environmental impact assessment (EIA) is therefore not needed as per EIA Directive 2014/52/EU amending Directive 2011/92/EU. The full environmental details will however be investigated by the Bank's services during the project due diligence.

Procurement

The Promoter has been assessed by the EIB as being a private company not subject to EU rules on public procurement or concessions. However, if at the project appraisal, the EIB were to conclude that the Promoter is subject to EU public procurement legislation then the Bank would duly inform the Commission Services and would require the Promoter to apply those rules.

Status

Signed - 5/12/2022

Milestone
Under appraisal
Approved
Signed
17 August 2022
5 December 2022

Disclaimer

Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).

Related tags

Spain Industry